F Dx Advisors, Inc. Novo Nordisk A S Transaction History

F Dx Advisors, Inc.

$362 Million
Q2 2024

A detailed history of F Dx Advisors, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, F Dx Advisors, Inc. holds 10,636 shares of NVO stock, worth $1.28 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares

10,636

Previous 39,682 73.2%

Holding current value

$1.28 Million

Previous $5.1 Million 70.21%

% of portfolio

0.42%

Previous 0.77%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	SELL	$122.71 - $146.91 $3.56 Million - $4.27 Million	-29,046 Reduced 73.2%	10,636 $1.52 Million
Q1 2024 May 03, 2024	SELL	$102.11 - $135.92 $2.01 Million - $2.67 Million	-19,680 Reduced 33.15%	39,682 $5.1 Million
Q4 2023 Feb 12, 2024	BUY	$87.78 - $105.45 $778,608 - $935,341	8,870 Added 17.57%	59,362 $6.14 Million
Q3 2023 Nov 02, 2023	BUY	$90.94 - $199.54 $1.52 Million - $3.34 Million	16,732 Added 49.56%	50,492 $4.59 Million
Q2 2023 Jul 17, 2023	BUY	$155.98 - $172.65 $471,995 - $522,438	3,026 Added 9.85%	33,760 $5.46 Million
Q4 2022 Feb 09, 2023	SELL	$102.55 - $135.33 $398,816 - $526,298	-3,889 Reduced 11.23%	30,734 $4.16 Million
Q3 2022 Nov 10, 2022	SELL	$95.28 - $116.93 $1.16 Million - $1.42 Million	-12,139 Reduced 25.96%	34,623 $3.45 Million
Q2 2022 Aug 03, 2022	SELL	$103.24 - $121.81 $1.59 Million - $1.87 Million	-15,388 Reduced 24.76%	46,762 $5.21 Million
Q1 2022 May 03, 2022	BUY	$93.1 - $112.54 $250,532 - $302,845	2,691 Added 4.53%	62,150 $6.9 Million
Q4 2021 Feb 01, 2022	BUY	$95.88 - $117.08 $333,470 - $407,204	3,478 Added 6.21%	59,459 $6.66 Million
Q3 2021 Oct 08, 2021	BUY	$84.42 - $106.62 $167,489 - $211,534	1,984 Added 3.67%	55,981 $5.38 Million
Q2 2021 Aug 05, 2021	BUY	$67.66 - $84.76 $477,679 - $598,405	7,060 Added 15.04%	53,997 $4.52 Million
Q1 2021 Apr 14, 2021	BUY	$67.06 - $75.82 $2.94 Million - $3.32 Million	43,773 Added 1383.47%	46,937 $3.16 Million
Q1 2021 Apr 13, 2021	SELL	$67.06 - $75.82 $2.87 Million - $3.25 Million	-42,824 Reduced 93.12%	3,164 $213,000
Q4 2020 Feb 08, 2021	BUY	$63.89 - $73.8 $219,589 - $253,650	3,437 Added 8.08%	45,988 $3.21 Million
Q3 2020 Nov 12, 2020	SELL	$63.69 - $70.22 $213,043 - $234,885	-3,345 Reduced 7.29%	42,551 $2.95 Million
Q2 2020 Jul 22, 2020	SELL	$58.54 - $67.94 $122,055 - $141,654	-2,085 Reduced 4.35%	45,896 $3.01 Million
Q1 2020 May 22, 2020	BUY	$49.46 - $64.78 $386,777 - $506,579	7,820 Added 19.47%	47,981 $2.89 Million
Q1 2020 May 13, 2020	SELL	$49.46 - $64.78 $296,463 - $388,291	-5,994 Reduced 12.99%	40,161 $67,000
Q4 2019 Feb 12, 2020	BUY	$49.86 - $58.26 $266,252 - $311,108	5,340 Added 13.08%	46,155 $2.67 Million
Q3 2019 Nov 07, 2019	BUY	$47.54 - $53.43 $159,972 - $179,791	3,365 Added 8.99%	40,815 $2.11 Million
Q2 2019 Jul 19, 2019	BUY	$46.79 - $52.47 $1.56 Million - $1.75 Million	33,271 Added 796.15%	37,450 $1.91 Million
Q1 2019 May 14, 2019	SELL	$46.36 - $52.63 $281,312 - $319,358	-6,068 Reduced 59.22%	4,179 $219,000
Q4 2018 Feb 07, 2019	BUY	$41.54 - $47.25 $176,295 - $200,529	4,244 Added 70.7%	10,247 $472,000
Q3 2018 Nov 13, 2018	SELL	$46.76 - $51.24 $81,596 - $89,413	-1,745 Reduced 22.52%	6,003 $283,000
Q2 2018 Aug 08, 2018	SELL	$44.29 - $50.42 $347,410 - $395,494	-7,844 Reduced 50.31%	7,748 $357,000
Q1 2018 May 02, 2018	SELL	$48.49 - $58.14 $163,314 - $195,815	-3,368 Reduced 17.76%	15,592 $768,000
Q4 2017 Feb 09, 2018	BUY	$47.53 - $53.73 $318,023 - $359,507	6,691 Added 54.54%	18,960 $1.02 Million
Q3 2017 Nov 03, 2017	SELL	$41.15 - $49.22 $68,555 - $82,000	-1,666 Reduced 11.96%	12,269 $591,000
Q2 2017 Aug 11, 2017	BUY	N/A	13,935	13,935 $598,000

Others Institutions Holding NVO

# of Institutions

1,991

Shares Held

318M

Call Options Held

5.23M

Put Options Held

4.97M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $273B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on F Dx Advisors, Inc. with notifications on news.

Account